0.8053
price down icon1.79%   -0.0147
after-market After Hours: .81 0.0047 +0.58%
loading

Indaptus Therapeutics Inc Stock (INDP) Latest News

pulisher
Feb 06, 2025

Indaptus Therapeutics expands cancer trial to Canada - Investing.com India

Feb 06, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics Files Prospectus Relating To Proposed Resale By Selling Stockholders Of Up To 4.4 Million Shares - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics expands cancer trial to Canada By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - The Manila Times

Feb 05, 2025
pulisher
Feb 05, 2025

Major Clinical Trial Expansion: Indaptus' Cancer Immunotherapy Decoy20 Gets Canadian Green Light - StockTitan

Feb 05, 2025
pulisher
Feb 03, 2025

Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

Indaptus Therapeutics Receives Notification from Nasdaq Regarding Minimum Bid Price RequirementUnited States Securities and Exchange Commission, Washington, DC 20549Form 8-KIndaptus Therapeutics, Inc. recently received a notification from Nasda - Defense World

Feb 01, 2025
pulisher
Jan 15, 2025

Indaptus Therapeutics looks to raise $2.25M in private placement - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Indaptus Therapeutics Announces $2.25 Million Private Placement - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in funding - Marketscreener.com

Jan 14, 2025
pulisher
Jan 13, 2025

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Indaptus Therapeutics Secures $2.25M Private Placement for R&D Advancement - StockTitan

Jan 13, 2025
pulisher
Jan 13, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 13, 2025
pulisher
Jan 08, 2025

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - The Manila Times

Jan 08, 2025
pulisher
Jan 08, 2025

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - GlobeNewswire Inc.

Jan 08, 2025
pulisher
Jan 08, 2025

Indaptus Therapeutics (NASDAQ:INDP) Trading Up 6.3% – Still a Buy? - Defense World

Jan 08, 2025
pulisher
Dec 27, 2024

INDP stock touches 52-week low at $0.81 amid market challenges - Investing.com Canada

Dec 27, 2024
pulisher
Dec 27, 2024

Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha

Dec 27, 2024
pulisher
Dec 23, 2024

Indaptus Therapeutics files to sell 1.94M shares of common stock - MSN

Dec 23, 2024
pulisher
Dec 14, 2024

Indaptus Therapeutics (NASDAQ:INDP) Shares Down 1% – Here’s Why - Defense World

Dec 14, 2024
pulisher
Dec 12, 2024

Gram-negative bacteria platform offers multiple immune receptor agonists for tumor immunotherapy - BioWorld Online

Dec 12, 2024
pulisher
Dec 01, 2024

Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 01, 2024
pulisher
Nov 24, 2024

Indaptus Therapeutics announces $2.135M registered direct offering - MSN

Nov 24, 2024
pulisher
Nov 23, 2024

Indaptus secures $2.1 million through stock and warrants sale By Investing.com - Investing.com Canada

Nov 23, 2024
pulisher
Nov 22, 2024

Indaptus secures $2.1 million through stock and warrants sale - Investing.com India

Nov 22, 2024
pulisher
Nov 22, 2024

Indaptus Therapeutics Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - citybiz

Nov 22, 2024
pulisher
Nov 22, 2024

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - The Manila Times

Nov 22, 2024
pulisher
Nov 22, 2024

Indaptus Therapeutics Secures $2.1M Direct Offering with Insider Participation | INDP Stock News - StockTitan

Nov 22, 2024
pulisher
Nov 22, 2024

Blackwell 3D to Attend The Big 5 Global Construction Show in Dubai - The Manila Times

Nov 22, 2024
pulisher
Nov 17, 2024

Maxim Group Has Lowered Expectations for Indaptus Therapeutics (NASDAQ:INDP) Stock Price - Defense World

Nov 17, 2024
pulisher
Nov 14, 2024

Indaptus Therapeutics Inc (INDP) Quarterly 10-Q Report - Quartz

Nov 14, 2024
pulisher
Nov 12, 2024

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 12, 2024
pulisher
Nov 11, 2024

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - The Manila Times

Nov 11, 2024
pulisher
Nov 07, 2024

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Indaptus' Decoy20 Shows Promise: Phase 1 Trial Reports Safe Weekly Dosing in Cancer Study | INDP Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy - Frontiers

Nov 07, 2024
pulisher
Oct 25, 2024

Rx Rundown: Opella, Samsung Biologics, Dimension and more - MM+M Online

Oct 25, 2024
pulisher
Oct 23, 2024

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Indaptus Therapeutics partners with BeiGene for cancer study By Investing.com - Investing.com Canada

Oct 23, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment - Morningstar

Oct 22, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics Announces Clinical Supply Agreement - GlobeNewswire

Oct 22, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations - The Manila Times

Oct 22, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics, Inc. Enters into Clinical Supply Agreement with Beigene Switzerland GmbH - Marketscreener.com

Oct 22, 2024
pulisher
Oct 15, 2024

Provident Bank's First-Time Home Buyer Survey Reveals That While Homeownership Continues to Be Challenging, Many Americans Are Finding Their Home in Less Than a Year - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Indaptus Therapeutics Initiates Unrestricted Enrollment of - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data - Investing.com

Oct 15, 2024
pulisher
Oct 13, 2024

Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20 - MSN

Oct 13, 2024
pulisher
Oct 10, 2024

Indaptus Therapeutics Founder and Chief Scientific Officer - GlobeNewswire

Oct 10, 2024
pulisher
Oct 08, 2024

Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times

Oct 08, 2024
pulisher
Sep 26, 2024

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 140.5% - Defense World

Sep 26, 2024
$79.89
price up icon 2.27%
$32.25
price up icon 1.67%
$4.47
price down icon 5.10%
$353.31
price up icon 2.22%
biotechnology ONC
$221.22
price up icon 0.71%
$114.50
price down icon 0.67%
Cap:     |  Volume (24h):